Ceva Animal Health Steps Up US Companion Animal Strategy with Leadership Changes and Relocations

Libourne, France, July 11, 2026: Ceva Animal Health is increasing its focus on the United States companion animal market, announcing two senior leadership moves aimed at accelerating growth in pet healthcare.

The French animal health company has appointed Laura Correro as Senior Vice President for the Companion Animals franchise. At the same time, Jean-Marcel Ciet, Executive Vice President for Global Companion Animals and a member of Ceva’s Executive Committee, will relocate to Bridgewater, New Jersey, the operational base of Ceva’s US commercial business.

The July 9 announcement sends a clear message: the United States is becoming a higher strategic priority for Ceva’s companion animal business.

Laura Correro to lead global companion animal strategy

In her new position, Correro will lead Ceva’s global companion animal strategy, with responsibility for growth, innovation and development of the company’s product portfolio across different sales and customer channels.

She brings more than 20 years of international experience in animal health and consumer healthcare, according to Ceva.

Her appointment is expected to give Ceva a stronger central focus as the company expands its pet health activities.

Jean-Marcel Ciet moves closer to the US market

The relocation of Jean-Marcel Ciet to New Jersey is equally significant. Ciet is a senior member of Ceva’s leadership team and is responsible for the company’s global companion animal business. Moving a group executive to the United States places senior decision-making closer to veterinarians, pet owners and commercial partners in the American market.

Ceva already has US operations covering research, manufacturing and field support, with products and services for companion animals, poultry and swine.

Why the United States matters to Ceva

The US is one of the world’s most important pet healthcare markets. High pet ownership, increasing spending on animal healthcare and growing demand for advanced treatments make the country a key growth market for global animal health companies.

For Ceva, the new leadership structure appears designed to bring its global companion animal strategy closer to the commercial realities of the US market.

This could help the company respond faster to customer needs, identify gaps in veterinary care and bring new products to a highly competitive market.

Companion animals becoming a bigger growth priority

Ceva is currently the world’s fifth-largest animal health company and operates in more than 110 countries. The group has more than 7,000 employees in 47 countries, 21 research and development centres and 32 production sites worldwide.

The company has built recognised positions in areas including animal vaccines, pharmaceuticals and behavioural health products for dogs and cats.

The latest appointments suggest that companion animal healthcare will play an increasingly important role in Ceva’s future growth strategy.

Ceva continues wider leadership and growth changes

The US move is also part of a broader period of change at Ceva. In April 2026, Ceva appointed Sébastien Huron as Deputy Chief Executive Officer, with responsibility for the group’s operational management. In May, the company named Ian Tarpey as Executive Vice President for Global Innovation and R&D.

Ceva has also been expanding through acquisitions and international partnerships, including its June 2026 acquisition of Aquilón to strengthen its position in swine intestinal health.

A stronger challenge in the global pet health market

The appointment of Laura Correro and Jean-Marcel Ciet’s relocation to the United States are more than routine management changes.

They indicate Ceva’s intention to compete more aggressively in the global companion animal health market, with the US at the centre of that strategy.

For the wider animal health industry, the move is another sign that pet healthcare remains a major growth battleground for global veterinary pharmaceutical companies, specifically in US which is by far the largest and most profitable pet healthcare market in the world.